LONDON and BOSTON, May 8, 2024 (Globe Newswire) — Treos Bio, a clinical-stage biotechnology company that uses data science and proprietary biomarkers to develop precision peptide immunotherapies, announced that it will announce new results from a Phase 2 trial of its flagship product. The combination of candidate polyPEPI1018 with Roche's PD-L1 inhibitor atezolizumab in patients with late-stage stable microsatellite metastatic colorectal cancer was presented at the 2024 ASCO Annual Meeting.
According to the World Health Organization, colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer-related death worldwide. According to the National Cancer Institute, approximately 1.4 million people in the United States have colorectal cancer. Current treatments for colorectal cancer include surgery and chemotherapy in the early stages of the disease, and chemotherapy, biologics, and targeted therapies in the later stages of the disease. Microsatellite stable (MSS) CRC accounts for approximately 85% of all colorectal cancers and nearly all cases of metastatic CRC (mCRC). MSS CRC patients do not benefit from available immunotherapies.
Treos' lead product candidate, PolyPEPI1018, is an off-the-shelf immunotherapy in clinical development for the treatment of metastatic colorectal cancer and was co-developed with a companion diagnostic candidate. This treatment is being developed as a first-line maintenance therapy and a third-line treatment. The companion diagnostic uses Treos' proprietary PASCal calculation tool to identify personal EPItopes (PEPIs) that have the potential to induce antigen-specific T-cell responses in patients.
Researchers reported that the results from OBERTO 301, a multicenter, open-label, phase 2 trial evaluating the combination of polyPEPI1018 and atezolizumab in patients with MSS mCRC who have progressed on two or three previous treatment regimens, We plan to present the new data in a poster. The study's primary endpoints were the incidence and severity of treatment-related adverse events, and secondary endpoints included objective response rate, duration of response, progression-free survival, and overall survival.
“We are very excited about the consistency observed in three clinical trials in different settings for MSS metastatic colorectal cancer and PolyPEPI1018’s unique ability to transform ‘cold’ tumors into ‘hot’ tumors. We are encouraged by this,” said Christopher C. Galen, MD. D., CEO of Treos Bio.
About Treos Bio Limited
Treos Bio uses proprietary computational data science that integrates HLA genetics, tumor profiles, and clinical outcomes from thousands of real-world subjects to develop precision peptide cancer immunotherapies in combination with novel biomarkers. I am. Treos has conducted three clinical trials in the United States and the European Union for its lead candidate polyPEPI1018, an off-the-shelf immunotherapy for the treatment of metastatic colorectal cancer. Treos has completed preclinical development of additional off-the-shelf immunotherapies for ovarian cancer, breast cancer, bladder cancer, gastric cancer, lung cancer, and melanoma. The company is also developing off-the-shelf immunotherapies customized to an individual patient's HLA genotype for several types of solid tumors. Treos has raised $45 million to date. For more information, please visit: www.treosbio.com.
contact:
Daniel Levin
Levine Media Group
danny@levinemediagroup.com
(510) 280-5405